BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Tikva Allocell Raises $8M Series A to Advance Off-the-Shelf CAR-T Therapy for Solid Tumours

Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targ...

July 24, 2026 | News

Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303

Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...

July 24, 2026 | News

Telix Doses First Patient in Phase 3 Trial of TLX250-Tx for Kidney Cancer

• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).&bul...

July 22, 2026 | News

China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer

SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...

July 21, 2026 | News

Telix Advances Illuccix Towards Japan Approval After Completing Phase III Patient Enrollment

Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data wil...

July 20, 2026 | News

Harbour BioMed, Kelun-Biotech Secure China IND Approval for Bispecific Antibody in Asthma

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o...

July 17, 2026 | News

Septa Pharmaceuticals Acquires CeeNU from Bristol Myers Squibb Canada

Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU...

July 17, 2026 | News

Telix Takes Next-Generation PSMA Radioligand Therapy into Earlier Prostate Cancer Treatment

First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sy...

July 17, 2026 | News

Boostimmune Secures Japanese Patent for TCTP-Targeting Antibody Technology to Advance Cancer Immunotherapy

Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulatio...

July 15, 2026 | News

Innovations in Hematologic Oncology: Addressing Unmet Needs in CLL Care

Lymphocyte Type, Blood Cancer Chronic lymphocytic leukaemia (CLL) is a blood malignancy caused by an overproduction of lymphocytes in the blood, lymphatic...

July 13, 2026 | Analysis

HanchorBio Partners with InxMed to Explore New Combination Strategies for Lead Cancer Therapy

Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist I...

July 13, 2026 | News

China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the biologics license application (BLA) for Op...

July 13, 2026 | News

LG Chem and OTR Therapeutics Partner to Advance China-Sourced Oncology Assets Globally

OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today an...

July 09, 2026 | News

World's First International Patient Begins Satri-cel Treatment at Jiahui International Cancer Center

Jiahui International Cancer Center (JICC) has welcomed the world's first international patient to begin treatment with Satri-cel, the world's first approve...

July 08, 2026 | News

Stay Connected